NLRP3 and metabolic dysfunction-associated steatohepatitis: It can be given by oral, intravenous, and i.p. routes and is effective at doses ranging from 4 to 20 mg/kg in mouse models of autoimmune disease (experimental autoimmune encephalitis) (14), diseases of constitutive NLRP3 activation (cryopyrin-associated periodic syndrome) (14), and disorders in which NLRP3 has been shown to play an important role [including cardiac infarction (25) and non-alcoholic steatohepatitis (26)].